Immunex/Ivax Paclitaxel ANDA Is First To File; Hauser Will Supply Bulk Drug
FDA has confirmed that the Immunex/Ivax paclitaxel ANDA was the first to be filed, Ivax announced Aug. 13. The decision will give the companies 180 days of marketing exclusivity upon approval of the ANDA.
You may also be interested in...
Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011